Sreenivas Rachakonda

This inventor holds 10 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignee: Natco Pharma Limited. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sreenivas Rachakonda. Retrieved from https://idiyas.com/inventor/sreenivas-rachakonda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 2)

% Patents Active = 60.0

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 22(Granted Patents)

Location History:

Andhra Pradesh, IN (2015)
Banjara Hills, IN (2016)
Hyderabad, IN (2011 - 2020)

Company Filing History:

10 out of 51

Natco Pharma Limited

patents

Years Active: 2011-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12729197 - Process for the preparation of venetoclax and its polymorphs thereof (2026-09-08),

2. 10870650 - Process for the preparation of amorphous idelalisib (2020-12-22),

3. 9440959 - Process for the preparation of nilotinib (2016-09-13),

4. 9061028 - Process for the preparation of Nilotinib (2015-06-23),

5. 8735415 - Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (2014-05-27),

6. 8183253 - Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase (2012-05-22),

7. 8067422 - Crystal form of phenylamino pyrimidine derivatives (2011-11-29),

8. 8048883 - Polymorphic form of imatinib mesylate and a process for its preparation (2011-11-01),

9. 7939541 - Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (2011-05-10),

10. 7910598 - Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase (2011-03-22),

Title: A Profile of Inventor Sreenivas Rachakonda

Introduction: Sreenivas Rachakonda, a prominent inventor based in Hyderabad, Telangana, India, has made significant contributions to the field of pharmaceuticals. With a total of nine patents to his name, Rachakonda is recognized for his innovative methodologies that enhance the efficacy and efficiency of drug production.

Latest Patents: Among his latest inventions, Rachakonda has developed a patented process for the preparation of amorphous Idelalisib. This inventive process focuses on the creation of a stable and pure amorphous form of Idelalisib, presenting a simple, economically viable, and efficient method suitable for industrial-scale production, while ensuring high chromatographic purity. Additionally, he has been involved in the patenting of a process for the preparation of Nilotinib, which encompasses a compound that offers therapeutic benefits as a pharmaceutical salt, demonstrating his commitment to advancing medicinal chemistry.

Career Highlights: Sreenivas Rachakonda is currently employed at Natco Pharma Limited, a leading pharmaceutical company in India known for its innovation in drug development. Through his work, Rachakonda has contributed to significant advancements in pharmaceutical processes, showcasing his expertise and dedication to the industry.

Collaborations: Throughout his career, Rachakonda has collaborated with notable colleagues including Amala Kompella and Bhujanga Rao Adibhatla Kali Satya. These partnerships have fostered an environment of shared knowledge and innovation, further enhancing the research and development initiatives at Natco Pharma Limited.

Conclusion: Sreenivas Rachakonda stands out as an influential inventor in the pharmaceutical sector, with a robust portfolio of patents that reflect his innovative spirit and technical expertise. His contributions play a crucial role in the advancement of drug manufacturing processes, pointing towards a promising future for pharmaceutical innovations in India.

Profile summary based on public USPTO records.